Antiperistaltic Effect and Safety of L-menthol in the Elderly With Contraindication to Buscopan
NCT ID: NCT04593836
Last Updated: 2020-10-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
60 participants
INTERVENTIONAL
2012-03-31
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Changes in Etomidate Dosage in Insomnia Patients Undergoing Digestive Endoscopy
NCT07028177
Phase III Controlled Clinical Study of NPO-11 in Patients Undergoing Gastric Endoscopy
NCT00742599
Effect of Oral Phloroglucin (FlospanĀ®) as Premedication of Non-sedative Diagnostic Esophagogastroduodenoscopy
NCT03342118
Application of Diaphragmatic Breathing in Patients With Disorders of Gut-brain Interaction
NCT06205446
The Impact of Comprehensive Education Before Gastroscopy on Improving the Tolerance of Patients
NCT03638752
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Traditionally, hyoscine-N-butylbromide (Buscopan) is the most commonly used drugs that inhibit intestinal peristalsis. But the side effects of drugs were mentioned in many studies, such as arrhythmia, increased glaucoma, dysuria in patients who have benign prostatic hypertrophy and allergic reactions, and may even cause anaphylactic shock. Peppermint oil is the extract of the natural plant (Mentha X piperita L) which was growth in North America and Europe. L-menthol is main component of peppermint oil. In animal experiments, peppermint oil had effect of calcium channel blockers and cause gastrointestinal smooth muscle relaxing effect. Clinically, peppermint oil preparations were used to relieve stress headache, non-ulcer dyspepsia and irritable bowel syndrome. The oral or intestinal local spraying of peppermint oil or L-menthol showed inhibition of intestinal peristalsis in many studies, and improved colonoscopy, barium enema, retrograde cholangiography , and upper gastrointestinal endoscopy examination.
With the aging of the population of Taiwan and the universality of endoscopy for elderly patients, the safety of endoscopy in elderly patients has more and more attention. According to ASGA guidelines, age is not a contraindication for endoscopy. But 50% of elderly patients have contraindications for hyoscine-N-butylbromide use. Therefore, effort to find alternative medicine to improve quality of endoscopy in elderly patients is necessary. Therefore, the investigators design a research for comparing effect and safety of L-menthol and placebo in elderly patients who have contraindication of hyoscine-N-butylbromide.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
L-menthol
20ml 0.8% L-menthol spray on the pyloric ring and observe the gastric peristalsis
L-menthol
20ml 0.8% L-menthol spray on the pyloric ring and observe the gastric peristalsis
Placebo
20ml 0.8% placebo spray on the pyloric ring and observe the gastric peristalsis
Placebo
20ml 0.8% placebo spray on the pyloric ring and observe the gastric peristalsis
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
L-menthol
20ml 0.8% L-menthol spray on the pyloric ring and observe the gastric peristalsis
Placebo
20ml 0.8% placebo spray on the pyloric ring and observe the gastric peristalsis
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* routine endoscopic examination
* Contraindication to Buscopan(such as arrhythmia, glaucoma, benign prostatic hyperplasia, ischemic heart disease...)
Exclusion Criteria
* The patient with critical illness are not suitable for the endoscopic examination
* Upper gastrointestinal bleeding
* Gastric tumor
* Gastric or duodenal ulcers are larger than 2 cm
* Severe pyloric obstruction or deformity
* Cancer patients received chemotherapy or radiation therapy
* Had peppermint allergy
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Taipei Veterans General Hospital, Taiwan
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ming-Chih Hou, MD
Role: PRINCIPAL_INVESTIGATOR
Taipei Veterans General Hospital, Taiwan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Taipei Veterans General Hospital
Taipei, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Yang TC, Chen PH, Hou MC, Peng LN, Lin MH, Chen LK, Huang YH. Antiperistaltic effect and safety of L-menthol for esophagogastroduodenoscopy in the elderly with contraindication to hyoscine-N-butylbromide. Sci Rep. 2022 Jun 21;12(1):10418. doi: 10.1038/s41598-022-14693-x.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
V101A-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.